Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

NewAmsterdam Pharma (NAMS) Return on Equity (2023 - 2025)

Historic Return on Equity for NewAmsterdam Pharma (NAMS) over the last 3 years, with Q3 2025 value amounting to 0.29%.

  • NewAmsterdam Pharma's Return on Equity rose 2300.0% to 0.29% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.29%, marking a year-over-year increase of 2300.0%. This contributed to the annual value of 0.46% for FY2024, which is 300.0% up from last year.
  • NewAmsterdam Pharma's Return on Equity amounted to 0.29% in Q3 2025, which was up 2300.0% from 0.21% recorded in Q2 2025.
  • NewAmsterdam Pharma's 5-year Return on Equity high stood at 0.21% for Q2 2025, and its period low was 0.57% during Q2 2024.
  • Moreover, its 3-year median value for Return on Equity was 0.43% (2024), whereas its average is 0.39%.
  • Its Return on Equity has fluctuated over the past 5 years, first tumbled by -2700bps in 2024, then skyrocketed by 3600bps in 2025.
  • NewAmsterdam Pharma's Return on Equity (Quarter) stood at 0.45% in 2023, then increased by 5bps to 0.43% in 2024, then soared by 31bps to 0.29% in 2025.
  • Its Return on Equity stands at 0.29% for Q3 2025, versus 0.21% for Q2 2025 and 0.24% for Q1 2025.